relapsing remitting multiple sclerosis

Summary

Summary: The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)

Top Publications

  1. Jongen P, Sindic C, Carton H, Zwanikken C, Lemmens W, Borm G. Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a. J Neurol. 2010;257:584-9 pubmed publisher
    In patients with relapsing remitting multiple sclerosis (RRMS), the effect of interferon-beta (INFb) on health-related quality of life (HR-QoL) is not firmly documented...
  2. Valentino P, Cerasa A, Chiriaco C, Nistico R, Pirritano D, Gioia M, et al. Cognitive deficits in multiple sclerosis patients with cerebellar symptoms. Mult Scler. 2009;15:854-9 pubmed publisher
    ..Cerebellar dysfunction is common in patients with multiple sclerosis (MS). However, neuropsychological studies of this clinical feature are lacking...
  3. Putzki N, Kollia K, Woods S, Igwe E, Diener H, Limmroth V. Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis. Eur J Neurol. 2009;16:424-6 pubmed publisher
    Natalizumab has been recommended for the treatment of patients with relapsing remitting multiple sclerosis with insufficient response to interferon-beta (IFN-beta) or glatiramer acetate (GA).
  4. Zamboni P, Galeotti R, Menegatti E, Malagoni A, Tacconi G, Dall Ara S, et al. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009;80:392-9 pubmed publisher
    ..The extracranial venous outflow routes in clinically defined multiple sclerosis (CDMS) have not previously been investigated...
  5. Cohen J, Barkhof F, Comi G, Hartung H, Khatri B, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402-15 pubmed publisher
    ..Fingolimod (FTY720), a sphingosine-1-phosphate-receptor modulator that prevents lymphocyte egress from lymph nodes, showed clinical efficacy and improvement on imaging in a phase 2 study involving patients with multiple sclerosis...
  6. Correale J, Ysrraelit M, Gaitán M. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain. 2009;132:1146-60 pubmed publisher
    ..and thirty-two Hispanic patients with clinically definite multiple sclerosis were studied, 58 with relapsing remitting multiple sclerosis during remission, 34 during relapse and 40 primary progressive multiple sclerosis cases...
  7. Kappos L, Gold R, Miller D, MacManus D, Havrdova E, Limmroth V, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;372:1463-72 pubmed publisher
    ..Oral fumarate (BG00012) might have dual anti-inflammatory and neuroprotective effects. Our aim was to assess the efficacy and safety of BG00012 in patients with relapsing-remitting multiple sclerosis...
  8. Mendozzi L, Tronci F, Garegnani M, Pugnetti L. Sleep disturbance and fatigue in mild relapsing remitting multiple sclerosis patients on chronic immunomodulant therapy: an actigraphic study. Mult Scler. 2010;16:238-47 pubmed publisher
    ..Poor sleep is common in MS and it contributes to fatigue. The beta interferons produce systemic effects which may not adapt and may induce fatigue...
  9. Kaiser C, Shukla D, Stebbins G, Skias D, Jeffery D, Stefoski D, et al. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. J Neuroimmunol. 2009;211:124-30 pubmed publisher
    ..These results show that pioglitazone was well tolerated in RRMS patients with indications of beneficial effects, warranting further trials to establish clinical efficacy...

More Information

Publications62

  1. Coles A, Compston D, Selmaj K, Lake S, Moran S, Margolin D, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359:1786-801 pubmed publisher
    ..Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, may be an effective treatment for early multiple sclerosis...
  2. O Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8:889-97 pubmed publisher
  3. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416-26 pubmed publisher
    ..Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing-remitting multiple sclerosis...
  4. Frischer J, Bramow S, Dal Bianco A, Lucchinetti C, Rauschka H, Schmidbauer M, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132:1175-89 pubmed publisher
    ..It further indicates that the disease processes of multiple sclerosis may die out in aged patients with long-standing disease...
  5. Kappos L, Radue E, O Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387-401 pubmed publisher
  6. Smolders J, Menheere P, Thewissen M, Peelen E, Tervaert J, Hupperts R, et al. Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosis. J Steroid Biochem Mol Biol. 2010;121:243-6 pubmed publisher
    ..These results suggest that the serum levels of 1,25(OH)2D, PTH, and total calcium are not critically involved in the correlation between vitamin D status and T cell regulation. ..
  7. Sipe J. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis. Expert Rev Neurother. 2010;10:365-75 pubmed publisher
    ..Assessments and conclusions will include a speculative 5-year outlook...
  8. Michel L, Berthelot L, Pettré S, Wiertlewski S, Lefrère F, Braudeau C, et al. Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis. J Clin Invest. 2008;118:3411-9 pubmed publisher
    ..The decreased inhibitory function of unfractioned CD4+CD25high cells previously observed might be due to abnormal activation of CD127high T cells in patients with MS...
  9. Birnbaum G, Cree B, Altafullah I, Zinser M, Reder A. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2008;71:1390-5 pubmed publisher
    ..To explore whether high-dose atorvastatin can be administered safely to persons with relapsing-remitting multiple sclerosis (MS) taking thrice weekly, 44 microg dose subcutaneous interferon beta-1a...
  10. Paul F, Waiczies S, Wuerfel J, Bellmann Strobl J, Dorr J, Waiczies H, et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS ONE. 2008;3:e1928 pubmed publisher
    ..Recent data from animal models of multiple sclerosis (MS) and from a pilot study indicated a possible beneficial impact of statins on MS...
  11. Freedman M, Hughes B, Mikol D, Bennett R, Cuffel B, Divan V, et al. Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison. Eur Neurol. 2008;60:1-11 pubmed publisher
    ..In the absence of head-to-head studies for all products used to treat RRMS, it still may be possible to compare treatment effects by applying evidence-based medicine principles...
  12. Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler. 2008;14:1220-4 pubmed publisher
    ..We investigated the association between serum levels of 25(OH)D and 1,25-dihydroxyvitamin D (1,25(OH)2D), the biologically active metabolite, and clinical MS severity as expressed by EDSS-score and relapse rate...
  13. Mikol D, Barkhof F, Chang P, Coyle P, Jeffery D, Schwid S, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7:903-14 pubmed publisher
    ..Our aim in the REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease) study was to compare interferon beta-1a with glatiramer acetate in patients with RRMS...
  14. Ge Y, Zohrabian V, Grossman R. Seven-Tesla magnetic resonance imaging: new vision of microvascular abnormalities in multiple sclerosis. Arch Neurol. 2008;65:812-6 pubmed publisher
    ..Ultrahigh-field (eg, 7-T) magnetic resonance imaging (MRI) has become a tool for assessing vascular involvement in MS lesions owing to markedly increased image resolution and susceptibility contrast of venous blood...
  15. Koch G, Rossi S, Prosperetti C, Codecà C, Monteleone F, Petrosini L, et al. Improvement of hand dexterity following motor cortex rTMS in multiple sclerosis patients with cerebellar impairment. Mult Scler. 2008;14:995-8 pubmed publisher
    ..rTMS of the motor cortex may be a useful approach to treat cerebellar impairment in MS patients...
  16. Scarisbrick I, Linbo R, Vandell A, Keegan M, Blaber S, Blaber M, et al. Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biol Chem. 2008;389:739-45 pubmed publisher
    ..These novel findings suggest that KLK1 and KLK6 may serve as serological markers of progressive MS and contribute directly to the development of neurological disability by promoting axonal injury and neuron cell death...
  17. Rocher F, Cohen M, Lebrun C. [Natalizumab (Tysabri) prescription practices of neurologists in southern France]. Rev Neurol (Paris). 2010;166:412-8 pubmed publisher
    Tysabri is indicated as single-drug disease-modifying therapy in patients with highly active relapsing remitting multiple sclerosis (RRMS)...
  18. Papuc E, Stelmasiak Z, Zbigniew S, Grieb P, Paweł G, Rejdak K, et al. CSF hypocretin-1 concentrations correlate with the level of fatigue in multiple sclerosis patients. Neurosci Lett. 2010;474:9-12 pubmed publisher
  19. Xu L, Xu Z, Xu M. Glucocorticoid treatment restores the impaired suppressive function of regulatory T cells in patients with relapsing-remitting multiple sclerosis. Clin Exp Immunol. 2009;158:26-30 pubmed publisher
    ..In conclusion, GC treatment restores the impaired T(reg) function in patients with RR-MS in its acute phase...
  20. Benedetti B, Rovaris M, Rocca M, Caputo D, Zaffaroni M, Capra R, et al. In-vivo evidence for stable neuroaxonal damage in the brain of patients with benign multiple sclerosis. Mult Scler. 2009;15:789-94 pubmed publisher
  21. Boster A, Hreha S, Berger J, Bao F, Penmesta R, Tselis A, et al. Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study. Arch Neurol. 2009;66:593-9 pubmed publisher
    ..To identify clinical and magnetic resonance imaging (MRI) features that distinguish progressive multifocal leukoencephalopathy (PML) from relapsing-remitting multiple sclerosis (RRMS)...
  22. Sosnoff J, Goldman M, Motl R. Real-life walking impairment in multiple sclerosis: preliminary comparison of four methods for processing accelerometry data. Mult Scler. 2010;16:868-77 pubmed publisher
    ..Such results provide preliminary evidence that variability in accelerometer counts is not simply noise and may provide important information about multiple sclerosis-related walking impairment...
  23. Glass Marmor L, Paperna T, Galboiz Y, Miller A. Immunomodulation by chronobiologically-based glucocorticoids treatment for multiple sclerosis relapses. J Neuroimmunol. 2009;210:124-7 pubmed publisher
    ..These findings provide preliminary characterization of biomarkers in the application of chronobiology-based glucocorticoid therapeutics in MS and other immune disorders...
  24. Reder A, Ebers G, Traboulsee A, Li D, Langdon D, Goodin D, et al. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Neurology. 2010;74:1877-85 pubmed publisher
    ..The 16-Year Long-Term Follow-Up (LTF) to the pivotal interferon-beta-1b (IFNbeta-1b) trial explored clinical, MRI, cognitive, and patient-reported outcomes. Here, we report the safety assessments...
  25. Antulov R, Weinstock Guttman B, Cox J, Hussein S, Durfee J, Caiola C, et al. Gender-related differences in MS: a study of conventional and nonconventional MRI measures. Mult Scler. 2009;15:345-54 pubmed publisher
    ..Studies showed gender-associated differences in multiple sclerosis (MS) disease evolution and in the evolution of conventional magnetic resonance imaging (MRI) findings...
  26. Matschay A, Nowakowska E, Hertmanowska H, Kus K, Czubak A. Cost analysis of therapy for patients with multiple sclerosis (MS) in Poland. Pharmacol Rep. 2008;60:632-44 pubmed
    ..00 (18,658.61euro) total for Group B and PLN 1,209.70 (310.98euro) per patient. Total direct and indirect costs for Group A and Group B amounted to PLN 5,595,968.58 (1,438,552.33euro) and PLN 1,655,658.30 (425,619.10euro), respectively...
  27. Bartolomei I, Salvi F, Galeotti R, Salviato E, Alcanterini M, Menegatti E, et al. Hemodynamic patterns of chronic cerebrospinal venous insufficiency in multiple sclerosis. Correlation with symptoms at onset and clinical course. Int Angiol. 2010;29:183-8 pubmed
    ..We investigated possible correlation between such hemodynamic patterns and both the symptoms at onset and clinical course in patients with MS and CCSVI...
  28. Kauffman M, Yankilevich P, Barrero P, Bello R, Marangunich L, Vidal A, et al. Whole genome analysis of the action of interferon-beta. Int J Clin Pharmacol Ther. 2009;47:328-57 pubmed
    ..To characterize the IFNbeta1a-regulated gene expression on leukocytes of Multiple Sclerosis (MS) patients using microarrays with whole human genome representation...
  29. Bermel R, Weinstock Guttman B, Bourdette D, Foulds P, You X, Rudick R. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. Mult Scler. 2010;16:588-96 pubmed publisher
  30. Fielding J, Kilpatrick T, Millist L, White O. Multiple sclerosis: Cognition and saccadic eye movements. J Neurol Sci. 2009;277:32-6 pubmed publisher
    ..This suggests that they could represent the foundation of a user-friendly surrogate marker of disease severity and progression in MS...
  31. Frisullo G, Nociti V, Iorio R, Patanella A, Caggiula M, Marti A, et al. Regulatory T cells fail to suppress CD4T+-bet+ T cells in relapsing multiple sclerosis patients. Immunology. 2009;127:418-28 pubmed publisher
    ..Moreover, the inhibitory capacity of CD4+ CD25+ T cells seems to be impaired in relapsing patients under inflammatory conditions, as shown by the high levels of T-bet expression in CD4+ T cells...
  32. Burgetova A, Seidl Z, Vaneckova M, Jakoubkova M. Concurrent occurrence of multiple sclerosis and primary CNS lymphoma: a case report. Neuro Endocrinol Lett. 2008;29:867-70 pubmed
    ..Advanced focus demand contrast- enhancing and mass- effect lesions. It is important to realize, that contrast-enhancement and brain edema may be mitigated by treatment with corticosteroids. In some cases a brain biopsy is needed...
  33. Conte A, Lenzi D, Frasca V, Gilio F, Giacomelli E, Gabriele M, et al. Intracortical excitability in patients with relapsing-remitting and secondary progressive multiple sclerosis. J Neurol. 2009;256:933-8 pubmed publisher
    ..It was found that intracortical excitability as measured with TMS differs according to the clinical course of MS; it remains normal in patients with low EDSS scores and is altered in patients with high EDSS scores...
  34. Portaccio E, Goretti B, Lori S, Zipoli V, Centorrino S, Ghezzi A, et al. The brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis. Mult Scler. 2009;15:620-6 pubmed publisher
  35. Poder K, Ghatavi K, Fisk J, Campbell T, Kisely S, Sarty I, et al. Social anxiety in a multiple sclerosis clinic population. Mult Scler. 2009;15:393-8 pubmed publisher
    ..Little is known about social anxiety in MS...
  36. Ravnborg M, Sørensen P, Andersson M, Celius E, Jongen P, Elovaara I, et al. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol. 2010;9:672-80 pubmed publisher
    ..We therefore aimed to investigate the combination of cyclic methylprednisolone and interferon beta for the treatment of relapsing-remitting multiple sclerosis...
  37. Isobe N, Matsushita T, Yamasaki R, Ramagopalan S, Kawano Y, Nishimura Y, et al. Influence of HLA-DRB1 alleles on the susceptibility and resistance to multiple sclerosis in Japanese patients with respect to anti-aquaporin 4 antibody status. Mult Scler. 2010;16:147-55 pubmed publisher
    ..Epistatic interactions between human leukocyte antigen (HLA)-DRB1 alleles alter multiple sclerosis (MS) risk in Caucasians. Such interactions have never been studied in Asian MS patients...
  38. De Riz M, Galimberti D, Fenoglio C, Piccio L, Scalabrini D, Venturelli E, et al. Cerebrospinal fluid progranulin levels in patients with different multiple sclerosis subtypes. Neurosci Lett. 2010;469:234-6 pubmed publisher
    ..A positive correlation between progranulin CSF levels and age was observed in patients (rho=0.29, P=0.03). According to these data, progranulin does not likely play a major role in the pathogenesis of MS...
  39. Smith C, Waubant E, Langer Gould A. Absence of neuromyelitis optica IgG antibody in an active relapsing-remitting multiple sclerosis population. J Neuroophthalmol. 2009;29:104-6 pubmed publisher
    ..We resolved to test for NMO antibody in a population of patients with active relapsing-remitting (RR) MS...
  40. Andreasen A, Spliid P, Andersen H, Jakobsen J. Fatigue and processing speed are related in multiple sclerosis. Eur J Neurol. 2010;17:212-8 pubmed publisher
    ..The objective of this study was to examine the relationship between processing speed and fatigue in patients with relapsing remitting MS...
  41. Romero Pinel L, Martinez Yelamos S, Gubieras L, Matas E, Bau L, Kremenchutzky M, et al. Anticipation of age at onset in familial multiple sclerosis. Eur J Neurol. 2010;17:572-5 pubmed publisher
    ..This study was performed to assess whether there is anticipation of age at onset in younger generations of familial multiple sclerosis (MS) in a Spanish population and to compare clinical characteristics of familial and sporadic MS...
  42. Newland P, Naismith R, Ullione M. The impact of pain and other symptoms on quality of life in women with relapsing-remitting multiple sclerosis. J Neurosci Nurs. 2009;41:322-8 pubmed
    ..Pain has significant nursing implications for women with RRMS. Pain often occurs in association with fatigue, depression, and sleep disturbance, which can lead to a decreased mental QOL...
  43. Stuve O, Leussink V, Frohlich R, Hemmer B, Hartung H, Menge T, et al. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis. Arch Neurol. 2009;66:259-61 pubmed publisher
    ..The clinical and paraclinical efficacy of rituximab was demonstrated recently in a phase 2 clinical trial in patients with RRMS...
  44. Burt R, Loh Y, Cohen B, Stefoski D, Stefosky D, Balabanov R, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol. 2009;8:244-53 pubmed publisher
    ..We evaluated the safety and clinical outcome of autologous non-myeloablative haemopoietic stem cell transplantation in patients with relapsing-remitting multiple sclerosis (MS) who had not responded to treatment with interferon beta...
  45. Banati M, Sandor J, Mike A, Illes E, Bors L, Feldmann A, et al. Social cognition and Theory of Mind in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2010;17:426-33 pubmed publisher
    ..Cognitive and mood dysfunctions have been recognized as common symptoms in multiple sclerosis (MS)...
  46. Cercignani M, Basile B, Spano B, Comanducci G, Fasano F, Caltagirone C, et al. Investigation of quantitative magnetisation transfer parameters of lesions and normal appearing white matter in multiple sclerosis. NMR Biomed. 2009;22:646-53 pubmed publisher
    ..This might reflect the complex interaction between demyelination, remyelination, gliosis, inflammation and axonal loss taking place within lesions...
  47. Nakamura M, Houzen H, Niino M, Tanaka K, Sasaki H. Relationship between Barkhof criteria and the clinical features of multiple sclerosis in northern Japan. Mult Scler. 2009;15:1450-8 pubmed publisher
  48. Dubois B. Multiple sclerosis: from cure to care. Verh K Acad Geneeskd Belg. 2009;71:295-300 pubmed
    ..The challenge for the future mainly consists in providing within this complexity the right treatment to the right individual and at the right moment...
  49. Ingram G, Hakobyan S, Hirst C, Harris C, Pickersgill T, Cossburn M, et al. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain. 2010;133:1602-11 pubmed publisher
    ..Serum factor H may be an effective indicator of progression and a practical and accessible biomarker and stratifying tool in determining disease course, providing objective evidence to help guide therapeutic decisions...
  50. Eissa A, Lebel R, Korzan J, Zavodni A, Warren K, Catz I, et al. Detecting lesions in multiple sclerosis at 4.7 tesla using phase susceptibility-weighting and T2-weighting. J Magn Reson Imaging. 2009;30:737-42 pubmed publisher
    ..To demonstrate 4.7 Tesla (T) imaging methods for visualizing lesions in multiple sclerosis in the human brain using phase susceptibility-weighting and T2 weighting...
  51. Yao K, Graham J, Akahata Y, Oh U, Jacobson S. Mechanism of neuroinflammation: enhanced cytotoxicity and IL-17 production via CD46 binding. J Neuroimmune Pharmacol. 2010;5:469-78 pubmed publisher
    ..Collectively, this study demonstrated evidence to suggest a potential mechanism of virus-induced neuroinflammation that may be involved in MS disease pathogenesis...
  52. Stich O, Janowitz D, Rauer S. Spontaneous intracerebral hemorrhage in a patient with multiple sclerosis and tumefactive demyelinating lesion. Mult Scler. 2009;15:517-9 pubmed publisher
    ..Neovascularization may contribute to tissue repair, particularly in large inflammatory cerebral lesions with increased vascular fragility. We discuss possible interaction of natalizumab with angiogenesis during tissue repair...
  53. Sadiq S, Puccio L, Brydon E. JCV detection in multiple sclerosis patients treated with natalizumab. J Neurol. 2010;257:954-8 pubmed publisher
    ..Screening for JCV in CSF in natalizumab-treated patients could help identify those at heightened risk for developing PML and discontinuing treatment in these patients may abort development of the clinical illness...